Coherus BioSciences Inc CHRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CHRS is a good fit for your portfolio.
News
-
Coherus BioSciences Gets FDA OK for Udenyca Injector
-
Intuitive Machines stock climbs on lunar mission plan as McDonald's edges higher ahead of results
-
Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi
-
Coherus BioSciences Gets FDA Approval for Loqtorzi, Chemotherapy Combination
-
Coherus BioSciences Shares Drop 9% on FDA's Application Rejection
-
Coherus: FDA Turns Away Udenyca On-Body Due to Filler Issues
-
Surface Oncology stock rallies on all-stock acquisition by Coherus
Trading Information
- Previous Close Price
- $2.07
- Day Range
- $1.96–2.09
- 52-Week Range
- $1.43–8.22
- Bid/Ask
- $1.98 / $2.04
- Market Cap
- $222.46 Mil
- Volume/Avg
- 1.4 Mil / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 306
- Website
- https://www.coherus.com
Comparables
Valuation
|
Metric
|
CHRS
|
TGTX
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 16.81 | — |
Price/Book Value | — | 12.57 | 2.93 |
Price/Sales | 0.76 | 8.47 | — |
Price/Cash Flow | — | 37.15 | — |
Price/Earnings
CHRS
TGTX
CELC
Financial Strength
|
Metric
|
CHRS
|
TGTX
|
CELC
|
|---|---|---|---|
Quick Ratio | 1.14 | 5.00 | 12.78 |
Current Ratio | 1.43 | 5.92 | 13.43 |
Interest Coverage | −4.88 | 2.04 | −12.43 |
Quick Ratio
CHRS
TGTX
CELC
Profitability
|
Metric
|
CHRS
|
TGTX
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −36.28% | 19.44% | −35.57% |
Return on Equity (Normalized) | — | 54.76% | −49.08% |
Return on Invested Capital (Normalized) | −46.62% | 35.76% | −39.21% |
Return on Assets
CHRS
TGTX
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Chphcvdnkx | Gkhvp | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sgkgwgsp | Zxwyxpm | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nvbwflc | Bfjbmh | $98.3 Bil | |
MRNA
| Moderna Inc | Yctxjlybv | Xtsj | $42.7 Bil | |
ARGX
| argenx SE ADR | Lgckhhz | Rqcb | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Frjnvbwsh | Nxr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kmzlmjwhk | Yvfvx | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jgzpcxnz | Zzwvdm | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yrkntdsty | Lgtrnw | $12.7 Bil | |
INCY
| Incyte Corp | Qdddlql | Vxvbyt | $11.8 Bil |